Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Verastem’s Copiktra Gets Early Approval To Challenge Zydelig, Venclexta In Third-Line CLL

25 Sep 2018

• By Joseph Haas

Cancer cells on scientific background.3d illustration

Related Content

Bayer's Aliqopa Approval Gives PI3K Class A Second Chance in Follicular Lymphoma

14 Sep 2017

Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie

06 Sep 2017

J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?

12 Jan 2018

Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan

08 Jun 2018

Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash

15 Jun 2016

100 More Jobs Cut At Infinity After AbbVie Inevitably Ends Partnership

29 Jun 2016

Related Companies

Verastem, Inc.

Infinity Pharmaceuticals, Inc.

AbbVie Inc.

Novartis AG

TG Therapeutics, Inc.

Gilead Sciences, Inc.

Bayer AG

Genentech, Inc.

Additional Topics

Approvals Commercial Business Strategies Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.